Meet the RESI November Speakers

4 Nov

By Caitlin Dolegowski, Marketing Specialist, LSN

Imagine learning critical components to successful fundraising from key experts and deal-makers in a virtual environment specific to early-stage life science and healthcare. It seems too good to be true until you check out the Digital RESI November lineup. Digital RESI November 16-18 offers attendees three days of panels, workshops and pitch sessions, each of which is designed to enrich the journey of early-stage, life science entrepreneurs with insight into what investors are looking for, how CEOs have found success and learning from other fundraising executives. Panel topics have been created to cover hot industry topics, with panelist recruitment focused on adding valuable content for fundraising attendees. Check out the panelists that will be presenting at this November’s conference below.

Partnering has begun for this conference and there is still time to register to attend!

Sangeeta Agarawal
Co-Founder & CEO
Helpsy Health 		Cynthia Cai
Venture Partner
Viva BioInnovator 		Mylea Charvat
Principal & Partner
LiquidSMARTS 		Jonathan Cohen
CEO
20/20 GeneSystems
Ruchi Dana
Board Member
Dana Group 		Nissim Darvish
Senior Managing Director (Israel)
OrbiMed Advisors LLC 		Dave Dlesk
CEO
Embrace Prevention Care 		Keren Etkin
Founder
TheGerontechnologist
Lana Feng
Co-Founder & CEO
HumaAI Inc 		Dave Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels 		Michael Fossel
President and Founder
Telocyte 		Les Funtleyder
Chief Investment Officer
TechNik
Shruti Gandhi
Founder & Managing Partner
Array Ventures 		Ernst Geutjes
Partner
Aglaia Oncology Funds 		Tom Gibbs
Director
Debiopharm Innovation Fund 		Kimberly Ha
Founder & CEO
KKH Advisors
André Harrell
Venture Partner
Cancer Fund 		Chihiro Hosoya
BD/VC Head, Rx+ Business Accelerator
Astellas Rx+ Business Accelerator 		Baudouin Hue
Partner
Karista 		Rachel Stillman, MBA
Senior Associate
7wire Ventures
Taha Jangda
Partner
HealthX Ventures 		Yury Kukushkin
Investment Director
JDRF T1D Fund 		Pepper Landson
CEO
Praetego Inc 		Taja Lester
Managing Partner
Health Equity Capital
Justin Leushner
Partner
Launchit Ventures 		Richard Lipkin
Co-Founder, Co-Chair
The Catalytic Impact Foundation 		Betsabeh Madani Hermann, MBA
Life Science and Healthcare Investor and Advisor 		Andrew Meadow
General Partner
Health Innovation Capital
Andy Merken
Partner, Corporate and Securities Co-Chair, Life Sciences
Burns & Levinson 		Brian Meshkin
Managing Partner
Profound Ventures 		Petra Meyer
Managing Director – HealthCare Sector Group Lead
Golden Seeds 		Christos Monovoukas
VP, Global M&A/Business Development
Olympus Corporation
Alex Morgan
Partner
Khosla Ventures 		Sasha Naydich
Associate
Myeloma Investment Fund 		Rohit Pratap Singh
Vice President, Investments
Xeraya Capital 		Rachel Rea
Director of Business Development and Licensing
Medtronic
Christina Salys
Director of New Business Development
Intuitive Surgical 		Beth Sanders
Founder & CEO
LifeBio Inc 		Diana Saraceni
Founder, Managing Director
Panakes Partners 		Rachel Scherl
CEO
SPARK Solutions for Growth
DJ (Dennis) Schmitt
Founder/CEO
Neuro20 Technologies 		Bryan Shao
K4 Deal Screening Committee
Keiretsu Forum 		Xuhui Shao
Managing Partner
Foothill Ventures 		Patrik Sobocki
Investment Manager Life Science
Industrifonden
Thomas Vogelsong
Investor/Life Science Advisor/Director, Deal Flow
KYTO Technology and Life Science 		Richard Ward
Director, Search and Evaluation, Oncology R&D BD
AstraZeneca 		Travis Whitfill
Partner
Bios Partners 		Thierry Wurch
Senior Director
Ipsen S.A.
Tiffany Yu
Vice President
Equality Asset Management LP 		Lu Zhang
Managing Partner
Fusion Fund

RESI-NOV-Banner-3050x-1050

Innovator’s Pitch Challenge – Finalists Announced!

4 Nov

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

At Digital RESI November we will again be showcasing top technologies across Drugs, Devices, Diagnostics and Digital Health in this edition of the Innovator’s Pitch Challenge. These companies will be featured on the RESI Live Agenda and will participate in live Pitch Sessions focused on a particular sector or indication, fielding questions from a panel of selected investors and industry experts.  The IPC has grown tremendously in popularity over the past year and attracts a big virtual audience, including investors and strategic partners.

Best of luck to the finalists!!

RESI-NOV-Banner-3050x-1050

The Future ETF of Early-Stage Investments

4 Nov

By Rory McCann, Marketing Manager & Conference Producer, LSN

KYTO Technology & Life Science is not your typical investment firm. They have a unique model that focuses on the financial investment, mentorship and advising, as well as growth and success of early-stage life science technology and their founding teams. Tom Vogelsong is the Director of Deal Flow and he sat down to discuss what makes KYTO’s outlook and processes different, the unique value they add to their portfolio, and exciting developments in the works.

KYTO is a frequent attendee and valuable asset to the RESI community. Get to know Tom and the team at Digital RESI November 16-18. Partnering is open, but there’s still time to sign up and book meetings! Register today to jumpstart your fundraising.

RESI-NOV-Banner-3050x-1050

Hot Investor Mandate: China-Based Government Sponsored Firm Actively Looks For Class II and III Medical Devices With China Market Potential for Investment or In-Licensing

4 Nov

Founded in 2019, a China-based firm sponsored by the local municipal government manages 2 funds that associated with their local incubator: one USD fund of $100MM and one RMB fund of $1,000MM, and is open to global in-licensing opportunities.

The firm focuses on Class II and Class III medical devices at the development stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to stroke, cardiovascular disease, eye disease, and medical robots. Currently, the firm is not interested in the IVD sector.

The firm prefers companies with a Chinese angle and are open to discussing China rights.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Pharmaceutical Company Seeks Investment and In-Licensing Opportunities in Oncology, Autoimmune Disease, Inflammation, and More

4 Nov

A venture arm of a pharmaceutical company is looking to make investments around $3 million in companies in the life science space. The firm could make as many as 2-3 investment over the next year and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities.

The firm is currently looking for companies developing therapeutics and is open to small molecules, biologics, and cell/gene therapy. The team is more interested in companies working with single assets although they can consider platform technologies. Indications of interest include Oncology, Inflammation, Orphan diseases, Critical care, Ophthalmology and Autoimmune diseases. The firm tends to be agnostic though and in spite of these focuses, is willing to look at most projects. The team looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The firm looking for privately held companies and prefers companies with experienced management teams in place. The team looks to act as a value-added investor through their strategic alignment with their parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Seeks New Investment Opportunities, With Strong Interest in Platform Technologies in All Indications

4 Nov

A venture capital firm based in the USA  has two funds under management and is currently investing out of its second fund. The firm seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $2 million to $4 million. The firm plans to invest in 2-3 companies over the next 12 months and prefers to invest in companies based in US or Canada.

The firm is currently looking for new investment opportunities in life sciences.  The firm is primarily focused on clinical stage biotech opportunities, and will consider any indication area.  The firm prefers to invest in platform technologies rather than single asset companies.

The firm generally seeks to invest in private companies. The firm has no specific requirements for the company’s management team, and sometimes takes a board seat when investing.  For therapeutics, Excel looks for companies that are developing platform technologies but have a clear plan on moving the lead program forward.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Firm With Strong Ties to Japanese Market Seeks to Invest in Companies in the Intersection of Life Sciences and Technology Addressing Unmet Medical Need

4 Nov

A professional firm provides management consulting and investment banking services in international corporate development to high technology companies.  The firm has been active in the healthcare sector for over 20 years working with Japanese clients that are looking for new business and/or technology opportunities both in medical device and pharmaceutical sectors. Currently, the firm does not manage its own VC funds but has access to funds prepared for direct investments or through CVCs by the firm’s clients in Japan. The firm is interested in companies from the seed stage through to late-stage venture rounds. The size of Investments varies by stage ranging from $0.5 Million to $3 Million. The firm is particularly interested in companies that have strong strategic fit with the Japanese market.

The firm’s primary focus is on the intersection between IT and Life Science, including POCT, telemedicine, among others.  Technologies involving sensors and materials science are also high focus areas.  For therapeutics, the firm generally does not invest in single-asset companies; therapeutic platform technologies that have the potential to create multiple ‘shots on goal’ are preferred.  The firm focuses on patients for whom there is high unmet need and no currently adequate treatments.  Rare diseases are of high interest.

The firm seeks management teams that exhibit knowledge of how to create a corporate value out of a strong technology.  The firm focuses on technologies that allow the firm’s clients to provide a value-add in joint R&D, manufacturing, or distribution.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →